1. Home
  2. STVN vs GKOS Comparison

STVN vs GKOS Comparison

Compare STVN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • GKOS
  • Stock Information
  • Founded
  • STVN 1949
  • GKOS 1998
  • Country
  • STVN Italy
  • GKOS United States
  • Employees
  • STVN N/A
  • GKOS N/A
  • Industry
  • STVN Containers/Packaging
  • GKOS Medical/Dental Instruments
  • Sector
  • STVN Consumer Discretionary
  • GKOS Health Care
  • Exchange
  • STVN Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • STVN 6.6B
  • GKOS 5.8B
  • IPO Year
  • STVN 2021
  • GKOS 2015
  • Fundamental
  • Price
  • STVN $25.38
  • GKOS $103.82
  • Analyst Decision
  • STVN Buy
  • GKOS Strong Buy
  • Analyst Count
  • STVN 6
  • GKOS 13
  • Target Price
  • STVN $25.08
  • GKOS $135.15
  • AVG Volume (30 Days)
  • STVN 322.5K
  • GKOS 845.8K
  • Earning Date
  • STVN 08-05-2025
  • GKOS 07-30-2025
  • Dividend Yield
  • STVN 0.24%
  • GKOS N/A
  • EPS Growth
  • STVN N/A
  • GKOS N/A
  • EPS
  • STVN 0.50
  • GKOS N/A
  • Revenue
  • STVN $1,215,562,040.00
  • GKOS $404,523,000.00
  • Revenue This Year
  • STVN $8.69
  • GKOS $27.88
  • Revenue Next Year
  • STVN $10.67
  • GKOS $27.60
  • P/E Ratio
  • STVN $50.81
  • GKOS N/A
  • Revenue Growth
  • STVN 3.81
  • GKOS 23.92
  • 52 Week Low
  • STVN $17.12
  • GKOS $77.10
  • 52 Week High
  • STVN $26.18
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • STVN 59.00
  • GKOS 57.69
  • Support Level
  • STVN $23.64
  • GKOS $101.30
  • Resistance Level
  • STVN $26.18
  • GKOS $106.82
  • Average True Range (ATR)
  • STVN 1.11
  • GKOS 3.17
  • MACD
  • STVN 0.06
  • GKOS 0.19
  • Stochastic Oscillator
  • STVN 78.61
  • GKOS 72.45

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: